[Skip to Navigation]
September 2003

Scoring With SCORTEN

Author Affiliations
  • 1Department of Dermatology, Solihull Hospital, Lode Lane, Solihull B91 2JL, England, e-mail: bethcollin@hotmail.com
  • 2Solihull
Arch Dermatol. 2003;139(9):1215. doi:10.1001/archderm.139.9.1215-a

We were interested to read the series of articles on the efficacy of intravenous immunoglobulin (IVIG) for the treatment of toxic epidermal necrolysis (TEN), published in the January issue of ARCHIVES. Most reports of trials of therapy in TEN are case series with no control group and so are difficult to interpret. The articles by Trent et al1 and Bachot et al2 address this by comparing actual mortality of IVIG-treated patients with mortality predicted by the SCORTEN prognostic scoring index.3

Add or change institution